•  
• Tweet
•  
•  
•        Print
•  
•        Email
•  
•         Track Keywords

Working with NEXTHERA's co-Founder and CIO, Ori Hershkovitz, Mazansky will help drive NEXTHERA's investment strategy of seeking high risk-adjusted returns from the healthcare and therapeutics sectors.

NEXTHERA is a NY based fundamental long/short equity fund concentrating in global therapeutics (large cap pharmaceuticals, specialty pharmaceuticals/generics, and biotech). The firm was founded by Ori Hershkovitz, formerly head of pharmaceutical research at Sphera Funds Management, Israel's largest hedge fund, and is a top authority on Teva (in and out of Israel), alongside Daniel Malek, who was previously allocating capital to external managers at EJS Investment S.A.

"We are excited to hire an individual with a long and impressive history in healthcare investing. Rael will strengthen our team as we continue to develop the best human capital to produce innovative research and guidance for the portfolio," said Daniel Malek, co-Founder and CEO. "Rael's experience and perspective will help NEXTHERA attempt to capitalize on dynamic opportunities in this often misunderstood and complex area."

Mazansky joins NEXTHERA after being a healthcare portfolio manager at Surveyor Capital (Citadel), and previously holding senior biotech analyst roles at Perceptive Advisors and Ridgeback Capital.